A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

por McKeage, Mark J, Gu, Yongchuan, Wilson, William R, Hill, Andrew, Amies, Karen, Melink, Teresa J, Jameson, Michael B
Publicado 2011

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

por McKeage, Mark J, Jameson, Michael B, Ramanathan, Ramesh K, Rajendran, Joseph, Gu, Yongchuan, Wilson, William R, Melink, Teresa J, Tchekmedyian, N Simon
Publicado 2012

The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in Non-Small Cell Lung Cancer

por Zhu, Hong, Hu, Yan, Zeng, Chenming, Chang, Linlin, Ge, Fujin, Wang, Weihua, Yan, Fangjie, Zhao, Qinxin, Cao, Ji, Ying, Meidan, Gu, Yongchuan, Zheng, Lin, He, Qiaojun, Yang, Bo
Publicado 2020

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice

por Gu, Yongchuan, Chang, Tony T.-A., Wang, Jingli, Jaiswal, Jagdish K., Edwards, David, Downes, Noel J., Liyanage, H. D. Sarath, Lynch, Courtney R. H., Pruijn, Frederik B., Hickey, Anthony J. R., Hay, Michael P., Wilson, William R., Hicks, Kevin O.
Publicado 2017